These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 38726789)

  • 1. PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease.
    Kumar M; Sharma AA; Datusalia AK; Khatik GL
    Med Chem; 2024; 20(8):781-798. PubMed ID: 38726789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.
    Sodhi RK; Singh N; Jaggi AS
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Aug; 384(2):115-24. PubMed ID: 21607645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.
    Wójtowicz S; Strosznajder AK; Jeżyna M; Strosznajder JB
    Neurochem Res; 2020 May; 45(5):972-988. PubMed ID: 32170673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.
    Luo R; Su LY; Li G; Yang J; Liu Q; Yang LX; Zhang DF; Zhou H; Xu M; Fan Y; Li J; Yao YG
    Autophagy; 2020 Jan; 16(1):52-69. PubMed ID: 30898012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
    Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional role of lipoprotein receptors in Alzheimer's disease.
    Jaeger S; Pietrzik CU
    Curr Alzheimer Res; 2008 Feb; 5(1):15-25. PubMed ID: 18288927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
    Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
    Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
    Agarwal S; Yadav A; Chaturvedi RK
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1166-1177. PubMed ID: 27514452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-128 knockout inhibits the development of Alzheimer's disease by targeting PPARγ in mouse models.
    Liu Y; Zhang Y; Liu P; Bai H; Li X; Xiao J; Yuan Q; Geng S; Yin H; Zhang H; Wang Z; Li J; Wang S; Wang Y
    Eur J Pharmacol; 2019 Jan; 843():134-144. PubMed ID: 30412727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
    Shackleton B; Crawford F; Bachmeier C
    Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration.
    Durai P; Beeraka NM; Ramachandrappa HVP; Krishnan P; Gudur P; Raghavendra NM; Ravanappa PKB
    Curr Neuropharmacol; 2022; 20(5):893-915. PubMed ID: 34751120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.
    Zolezzi JM; Inestrosa NC
    Mol Neurobiol; 2013 Dec; 48(3):438-51. PubMed ID: 23494748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.
    Zolezzi JM; Santos MJ; Bastías-Candia S; Pinto C; Godoy JA; Inestrosa NC
    Biol Rev Camb Philos Soc; 2017 Nov; 92(4):2046-2069. PubMed ID: 28220655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of PPARs in Disease.
    Wagner N; Wagner KD
    Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
    Menendez-Gutierrez MP; Roszer T; Ricote M
    Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation.
    Li Z; Li H; Zhao C; Lv C; Zhong C; Xin W; Zhang W
    CNS Neurol Disord Drug Targets; 2015; 14(3):360-9. PubMed ID: 25714973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.